AbbVie Valuation
| ABBV Stock | USD 183.08 1.94 1.07% |
At this time, the firm appears to be overvalued. AbbVie Inc shows a prevailing Real Value of $171.99 per share. The current price of the firm is $183.08. Our model approximates the value of AbbVie Inc from analyzing the firm fundamentals such as return on equity of 0.56, and Profit Margin of 0.09 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AbbVie's valuation include:
Price Book 53.0669 | Enterprise Value 383.9 B | Enterprise Value Ebitda 21.0618 | Price Sales 5.7641 | Forward PE 15.2672 |
Overvalued
Today
Please note that AbbVie's price fluctuation is very steady at this time. Calculation of the real value of AbbVie Inc is based on 3 months time horizon. Increasing AbbVie's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AbbVie stock is determined by what a typical buyer is willing to pay for full or partial control of AbbVie Inc. Since AbbVie is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AbbVie Stock. However, AbbVie's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 183.08 | Real 171.99 | Target 160.21 | Hype 183.14 | Naive 185.2 |
The intrinsic value of AbbVie's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AbbVie's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AbbVie Inc helps investors to forecast how AbbVie stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AbbVie more accurately as focusing exclusively on AbbVie's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AbbVie's intrinsic value based on its ongoing forecasts of AbbVie's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AbbVie's closest peers.
AbbVie Cash |
|
AbbVie Valuation Trend
Analysing the historical paterns of AbbVie's enterprise value and its market capitalization is a good way to estimate and gauge the value of AbbVie Inc over time and is usually enough for investors to make rational market timing decisions.
AbbVie Revenue by Product
AbbVie Total Value Analysis
AbbVie Inc is presently forecasted to have valuation of 383.89 B with market capitalization of 320.1 B, debt of 59.38 B, and cash on hands of 11.88 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AbbVie fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
383.89 B | 320.1 B | 59.38 B | 11.88 B |
AbbVie Investor Information
About 73.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.43. AbbVie Inc last dividend was issued on the 15th of January 2025. Based on the measurements of operating efficiency obtained from AbbVie's historical financial statements, AbbVie Inc may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.32 | 0.2349 |
|
| |||||
| Total Cash From Operating Activities | 12.6 B | 22.8 B |
|
| |||||
| Operating Income | 9.8 B | 12.8 B |
|
|
AbbVie Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AbbVie has an asset utilization ratio of 40.32 percent. This indicates that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that AbbVie Inc is more efficient with each dollar of assets it utilizes for everyday operations.AbbVie Ownership Allocation
AbbVie holds a total of 1.77 Billion outstanding shares. The majority of AbbVie Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AbbVie Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AbbVie. Please pay attention to any change in the institutional holdings of AbbVie Inc as this could imply that something significant has changed or is about to change at the company. On November 22, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of AbbVie Inc's common stock.AbbVie Profitability Analysis
The company reported the previous year's revenue of 54.32 B. Net Income was 4.88 B with profit before overhead, payroll, taxes, and interest of 41.53 B.AbbVie Past Distributions to stockholders
About AbbVie Valuation
Our relative valuation model uses a comparative analysis of AbbVie. We calculate exposure to AbbVie's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AbbVie's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 45.5 B | 25.2 B | |
| Pretax Profit Margin | 0.12 | 0.11 | |
| Operating Profit Margin | 0.23 | 0.32 | |
| Net Profit Margin | 0.09 | 0.09 | |
| Gross Profit Margin | 0.62 | 0.80 |
A single share of AbbVie represents a small ownership stake in the entity. As a stockholder of AbbVie, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
AbbVie Dividends Analysis For Valuation
Dividend Payout Ratio is likely to climb to 2.28 in 2024, whereas Dividends Paid is likely to drop slightly above 6.6 B in 2024. . Price Earnings Ratio is likely to climb to 59.16 in 2024, despite the fact that Retained Earnings are likely to grow to (950 M).
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 10.5 B | 6.6 B | |
| Dividend Yield | 0.04 | 0.03 | |
| Dividend Payout Ratio | 2.17 | 2.28 | |
| Dividend Paid And Capex Coverage Ratio | 2.02 | 1.92 |
There are various types of dividends AbbVie can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of AbbVie shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from AbbVie Inc directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When AbbVie pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of AbbVie by the value of the dividends paid out.
AbbVie Growth Indicators
Investing in growth stocks can be very risky. If the company such as AbbVie does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.8 B | |
| Quarterly Earnings Growth Y O Y | -0.123 | |
| Forward Price Earnings | 15.2672 |
AbbVie Current Valuation Indicators
AbbVie's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AbbVie's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AbbVie, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AbbVie's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AbbVie's worth.Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.